A number of research firms have changed their ratings and price targets for Incyte (NASDAQ: INCY):
- 10/10/2026 – Incyte was downgraded by Wall Street Zen from “buy” to “hold”.
- 10/8/2026 – Incyte was upgraded by Weiss Ratings from “buy (b)” to “buy (b+)”.
- 10/8/2026 – Incyte had its price target raised by Royal Bank Of Canada from $109.00 to $114.00. They now have a “sector perform” rating on the stock.
- 10/5/2026 – Incyte had its “neutral” rating reaffirmed by UBS Group AG. They now have a $127.00 price target on the stock.
- 10/5/2026 – Incyte had its price target raised by Stifel Nicolaus from $145.00 to $157.00. They now have a “buy” rating on the stock.
- 10/1/2026 – Incyte had its price target raised by Wells Fargo & Company from $116.00 to $128.00. They now have an “equal weight” rating on the stock.
- 9/28/2026 – Incyte had its “buy” rating reaffirmed by UBS Group AG.
- 9/28/2026 – Incyte had its price target raised by JPMorgan Chase & Co. from $120.00 to $123.00. They now have a “neutral” rating on the stock.
- 9/28/2026 – Incyte had its price target raised by HC Wainwright from $150.00 to $152.00. They now have a “buy” rating on the stock.
- 9/22/2026 – Incyte had its “sector perform” rating reaffirmed by Royal Bank Of Canada. They now have a $109.00 price target on the stock.
- 9/12/2026 – Incyte was upgraded by Wall Street Zen from “hold” to “buy”.
- 9/11/2026 – Incyte had its “neutral” rating reaffirmed by Cantor Fitzgerald.
- 9/1/2026 – Incyte had its “market perform” rating reaffirmed by BMO Capital Markets.
- 8/29/2026 – Incyte was upgraded by Wall Street Zen from “hold” to “buy”.
- 8/24/2026 – Incyte was upgraded by TD Cowen to “strong-buy”.
- 8/20/2026 – Incyte had its “buy” rating reaffirmed by Benchmark Co..
- 8/20/2026 – Incyte is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $152.00 price target on the stock.
- 8/20/2026 – Incyte had its “buy” rating reaffirmed by HC Wainwright. They now have a $150.00 price target on the stock.
- 8/17/2026 – Incyte had its price target raised by Piper Sandler from $110.00 to $130.00. They now have an “overweight” rating on the stock.
- 8/13/2026 – Incyte had its “market perform” rating reaffirmed by Sanford C. Bernstein. They now have a $104.00 price target on the stock.
Insider Transactions at Incyte
In other news, EVP Patrick Mayes sold 41,899 shares of the business’s stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $119.46, for a total transaction of $5,005,254.54. Following the completion of the sale, the executive vice president owned 61,441 shares in the company, valued at approximately $7,339,741.86. The trade was a 40.54% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Pablo Cagnoni sold 10,801 shares of the stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $125.56, for a total transaction of $1,356,173.56. Following the sale, the insider directly owned 183,200 shares of the company’s stock, valued at approximately $23,002,592. This trade represents a 5.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 16.20% of the stock is currently owned by insiders.
Incyte’s marketed portfolio includes Jakafi (ruxolitinib), a JAK inhibitor used in the United States for certain myelofibrosis, polycythemia vera and graft-versus-host disease indications, and Opzelura (ruxolitinib) cream for certain inflammatory skin conditions.
Read More
- Five stocks we like better than Incyte
- Salesforce Just Got a Rare Double Upgrade—What Changed?
- OpenAI’s Revenue Scare Could Be a Big Opportunity for Investors
- China Still Dominates Rare Earths—These 3 U.S. Companies Could Benefit
- 3 REITs That May Win in a Higher Interest Rate Environment
Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
